Actively Recruiting
Bank of Human Leukocytes From COVID-19 Convalescent Donors With an Anti-SARS-CoV-2 Cellular Immunity
Led by Central Hospital, Nancy, France · Updated on 2025-08-08
32
Participants Needed
1
Research Sites
171 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The SARS-CoV-2 identified in China in January 2020 is the cause of an unprecedented pandemic. The SARS-CoV-2 and each viral variant are responsible of a respiratory infectious disease, which can be asymptomatic. Nevertheless, a part of infected patients will experiment serious forms associated with a high mortality rate. Most serious forms present with lymphopenia and a functional exhaustion of speicifci T lymphocytes. Several studies showed that these quantitative and qualitative lymphocyte abnormalities are associated with unfavourable patients' outcome. The investigators hypothesized that the use of anti-viral T lymphocytes from convalescent COVID 19 donors could be helpful to improve the prognosis of COVID-19 serious forms. This study aims to demonstrate the feasibility of setting up a biobank that could allow the preservation and production of a cellular immunotherapy specific to SARS-CoV-2.
CONDITIONS
Official Title
Bank of Human Leukocytes From COVID-19 Convalescent Donors With an Anti-SARS-CoV-2 Cellular Immunity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Hospitalized for confirmed COVID-19 infection at Nancy University Hospital
- Received comprehensive information about the study and agreed to participate
- Has active cellular immunity against SARS-CoV-2 defined by Elispot IFNgamma > 50 SFC/10^6 PBMC
You will not qualify if you...
- Hospitalized in intensive care unit
- Hemoglobin level less than 10 g/dl
- Taking hypertension medication
- History of cardiovascular disease including valvulopathy, conduction rhythm disorders, arterial vascular insufficiency, or congenital anomalies
- Presence of autoimmune disease
- History of solid or hematopoietic graft
- Active malignant disease or remission less than 2 years
- Psychiatric disorders
- Under legal protection measures
- Proven infectious disease
- Asplenic
- Pregnant or breastfeeding women
- Women not using contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHRU-Nancy - Hopitaux de Brabois - Batiment Philippe Canton
Vandœuvre-lès-Nancy, Lorraine, France, 54511
Actively Recruiting
Research Team
B
Benjamin Lefèvre
CONTACT
D
Danièle Bensoussan
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here